Department of Neurosurgery, Oulu University Hospital, PO Box 21, 90029 OYS, Oulu, Finland.
Eur J Neurol. 2010 May;17(5):708-14. doi: 10.1111/j.1468-1331.2009.02912.x. Epub 2010 Feb 2.
Hypertension is the most important modifiable risk factor for primary intracerebral hemorrhage (ICH), but little is known of the effect of preceding hypertension on outcome. Because high mean arterial blood pressure (MABP) at admission is an independent predictor of early death in patients with ICH, we explored its role on survival and poor outcome separately in normotensive subjects and subjects with treated and untreated hypertension.
We assessed clinical data and the 3-month outcome of patients with spontaneous ICH (n = 453) admitted to the stroke unit of Oulu University Hospital between 1993 and 2004. Standard medical treatment was used to lower MABP from levels >127 mmHg to <120 mmHg.
Overall mortality within 3 months was 28%. Patients with untreated hypertension had significantly lower mortality (6%) than those with treated hypertension (36%, P < 0.001) or those without hypertension (25%, P < 0.01). High admission MABP associated with early death in normotensive subjects (P < 0.05) and those on medication for hypertension (P < 0.01) but not in those with untreated hypertension. Patients with untreated hypertension were younger and had less frequently cardiac disease, diabetes, and/or warfarin or aspirin medications, but they showed the highest blood pressures (BPs) at admission. Amongst patients with high admission MABP, favorable outcome was seen most frequently in those who had untreated hypertension. Hematoma growth did not associate with high MABP amongst them.
Despite their higher BP values at admission, subjects with untreated hypertension showed better survival and more frequently favorable outcome after BP-lowering therapy than other patients.
高血压是原发性脑出血(ICH)最重要的可改变危险因素,但对于既往高血压对预后的影响知之甚少。由于入院时平均动脉压(MABP)升高是 ICH 患者早期死亡的独立预测因素,因此我们分别在正常血压受试者、治疗和未治疗高血压受试者中探讨了其对生存和不良预后的作用。
我们评估了 1993 年至 2004 年间入住奥卢大学医院卒中单元的自发性 ICH 患者(n = 453)的临床数据和 3 个月的预后。使用标准药物治疗将 MABP 从 >127mmHg 降至 <120mmHg。
3 个月内的总体死亡率为 28%。未治疗的高血压患者的死亡率明显较低(6%),低于治疗的高血压患者(36%,P < 0.001)或无高血压患者(25%,P < 0.01)。入院时的高 MABP 与正常血压受试者(P < 0.05)和服用降压药物的高血压受试者(P < 0.01)的早期死亡相关,但与未治疗的高血压受试者无关。未治疗的高血压患者更年轻,且较少患有心脏病、糖尿病和/或华法林或阿司匹林药物,但他们的入院血压最高。在入院时 MABP 较高的患者中,最常观察到未治疗的高血压患者有良好的预后。血肿增大与他们的高 MABP 无关。
尽管入院时血压值较高,但与其他患者相比,未治疗的高血压患者在降压治疗后生存状况更好,且更常出现良好预后。